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ABSTRACT
RNA binding proteins (RBPs) play a central role in cell physiology and pathology. 
Among them, HuR is a nuclear RBP, which shuttles to the cytoplasm to allow its RNA 
targets processing. HuR over-expression and delocalization are often associated to 
cell transformation. Numerous cancers display increased HuR protein levels and its 
high cytoplasmic levels has been associated with a worse prognosis.
In our study, we first evaluated HuR expression in normal and cancer thyroid 
tissues and then evaluated its function in thyroid cell lines. HuR is over-expressed 
in all thyroid tumor tissues; high cytoplasmic levels are detected in all thyroid 
carcinomas. HuR silencing decreased cell viability and determined apoptotic cell 
death, in a non-tumorigenic (Nthy-ori-3.1) and a tumorigenic (BCPAP) thyroid cell 
line. Global transcriptome analysis indicated that HuR silencing, though having similar 
biological effects, induces distinct gene expression modifications in the two cell lines. 
By using the RIP-seq approach, the HuR-bound RNA profiles of different thyroid cell 
lines were evaluated. We show that in distinct cell lines HuR-bound RNA profiles are 
different. A set of 114 HuR-bound RNAs distinguishing tumorigenic cell lines from the 
non-tumorigenic one was identified.
Altogether, our data indicate that HuR plays a role in thyroid tumorigenesis. 
Moreover, our findings are a proof of concept that RBP targets differ between cells 
with the same origin but with distinct biological behavior.
INTRODUCTION
Gene expression regulation is an essential process 
by which cells react to microenvironment changes. One 
of the key mechanisms of gene expression regulation 
occurs at post-transcriptional levels, i.e on mRNA [1]. 
RNA regulation allows cells to react to environmental 
stimuli more quickly than de novo transcription. In fact, 
many important cellular processes, such as proliferation, 
differentiation and apoptosis, are regulated by post-
transcriptional mechanisms controlling RNA stability, 
localization and translation [2].
In eukaryotic cells, RNAs is associated with RNA-
binding proteins (RBPs), a protein family that can bind 
single or double stranded RNA to form ribonucleoprotein 
complexes (RNPs) [3]. RBPs regulate all phases of RNA 
biogenesis, including splicing, capping, 3’ end formation, 
nucleocytoplasmic transport, localization, translation and 
degradation [4].
RBPs bind their targets in particular sequences or 
to specific secondary structures, located especially in the 
untranslated regions (UTRs). The specific bound between 
regulatory proteins and these elements is achieved by 
RNA-binding domains (RBDs) [4]. Currently more than 
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40 RBDs have been identified and, if we consider that a 
RBP can contain one or, more often, various combinations 
of different RBDs, it is not that hard to understand the high 
flexibility of the interaction with different targets [3, 4].
Alteration in RBP activities or RBP-targets 
interactions could be damaging for gene expression 
regulation [5]. Moreover, an aberrant RBP expression 
has been unveil in several diseases, such as muscular 
atrophies, neurological disorders and cancer [6]. Indeed, 
in many neoplasia, it has been described an altered 
expression of several RBPs, which act by changing their 
binding to tumor tissue-specific oncogenes or tumor 
suppressors [4].
The human embryonic lethal abnormal vision-like 
protein (ELAVL1 or HuR) is a member of the Hu family of 
RNA-binding proteins and is one of the most remarkable 
RBP known to be implicated in tumorigenesis [4, 7, 8].
HuR binds its mRNA targets through its RNA 
recognition motifs (RRMs) which recognize sequences 
rich in adenosine/uridine or uridine (AREs), that are 
mostly localized in the transcript non-coding regions, 
such as introns and the 3’ untranslated region [9]. In 
physiological conditions, HuR is located into the nucleus, 
but can shuttle to the cytoplasm to allow its mRNA target 
to be processed. Since transcripts coding for important 
tumorigenesis factors, oncogenes, growth and anti-
apoptotic factors are described among HuR targets, it is 
not surprising that an aberrant over-expression of HuR 
is associated to cellular transformation [8, 9]. Indeed, 
heightened HuR protein levels have been observed in 
numerous cancers [4]. Furthermore, high HuR cytoplasmic 
levels are known to be associated with a worse prognosis 
in many tumor types, including lung adenocarcinoma, gall 
bladder carcinoma, urothelial carcinoma, ovarian cancer, 
breast cancer, laryngeal squamous cell cancer and colon 
cancer [8-10].
Thyroid cancer is the most frequent endocrine 
neoplasm and its incidence has been enhanced in the 
last decade [11]. Most of thyroid carcinomas derived 
from follicular cells are classified in papillary, follicular 
and anaplastic thyroid cancer (PTC, FTC, and ATC, 
respectively). PTC and FTC maintains a certain degree of 
differentiation and are also named differentiated thyroid 
carcinomas (DTC) [12]. Although most of DTCs has a 
favorable outcome, some of them show an aggressive 
behavior [13]. Nowadays there are not molecular markers 
able to efficiently discriminate DTC with different 
aggressiveness.
In this study, we assessed HuR levels in human 
thyroid tissues and cell lines, comparing normal and cancer 
samples. We demonstrated a general HuR overexpression 
in thyroid tumors and that cytoplasmic HuR staining could 
discriminates malignant from benign lesions. We then 
investigated the effects of HuR silencing in thyroid tumor 
and non-cancerous cell lines, evaluating cell viability and 
global gene expression profiles modification. Finally, 
we delineated the HuR-bound RNA profiles in different 
thyroid cell lines. Altogether, our data provide the proof 
of principle that investigation on RNA binding proteins 
could provide clues for understanding of mechanisms 
underlining tumorigenesis of thyroid follicular cells.
RESULTS
HuR expression in thyroid tissues
In a first set of experiments we evaluated HuR 
protein expression and its sub-cellular localization in 
normal and tumor thyroid tissues. For this purpose we 
created a tissue microarray composed by 12 normal 
thyroid samples (NTs), 25 follicular adenomas (FAs), 23 
follicular thyroid carcinomas (FTCs), 36 papillary thyroid 
carcinomas (PTCs) and 8 anaplastic thyroid carcinomas 
(ATCs), in order to perform an immunohistochemical 
HuR evaluation. Representative images of HuR staining 
are shown in panel A of Figure 1, indicating that all tumors 
displayed an increased HuR staining if compared to NT. 
However, important differences have been highlighted 
when nuclear and cytoplasmic staining were separately 
analyzed. Nuclear staining was significantly increased in 
all tumors, FAs included (Figure 1, Panel B, left side). In 
contrast, cytoplasmic staining shows dramatic differences 
between NT and FAs, on one side, and all malignancies on 
the other one (Figure 1, Panel B, right side). The higher 
cytoplasmic staining was observed in the PTC group, in 
which a 5-fold increment was observed in comparison to 
normal tissue. However, a wide variation of cytoplasmic 
staining was observed in PTCs (see also representative 
images in Panel A of Figure 1). Nevertheless, cytoplasmic 
HuR staining clearly discriminates between not only 
normal and tumor tissue, but even between malignant and 
benign neoplasia.
Based on immunohistochemical findings that 
suggest a relevant role of HuR in thyroid tumorigenesis, 
we used Western blot to evaluate expression of this protein 
in several thyroid cell lines. In particular, HuR protein 
levels were assessed in a non-tumorigenic thyroid cell 
line (Nthy-ory-3.1) and in six thyroid cancer cell lines 
(BCPAP, TPC1, FTC133, WRO, FRO and SW1736). As 
observed in thyroid tumor tissue, the Western blot analysis 
displayed a significant HuR over-expression in PTC cell 
lines and in SW1736 cells (Figure 2, Panel A-B). Thus, 
for further investigation we decided to use Nthy-ori-3.1, 
as model of non-tumorigenic thyroid cells and BCPAP, 
as model of tumorigenic ones. The HuR subcellular 
localization was assessed in Nthy-ori-3.1 and BCPAP 
cell lines by immunocytochemistry. As shown in Figure 
2 (Panel C) HuR staining positivity was higher in BCPAP 
than in Nthy-ori-3.1. A higher HuR staining positivity was 
observed in BCPAP compared to Nthy-ory-3.1. Both cell 
lines show a HuR nuclear staining, which appears more 
prominent in the tumor cell line.
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HuR silencing effects
In order to evaluate biological HuR-related effects 
in thyroid cells, we performed an RNA interference assay. 
After HuR silencing, no protein levels were detectable 
by immunoblot analysis both in Nthy-ory-3.1 and in 
BCPAP (Figure 3, Panel A). Since it is described that 
HuR silencing could increase apoptotic phenomena [14], 
we analyzed cell viability and apoptosis levels after HuR 
silencing, by Annexin V/PI assay. In both cell lines, HuR 
silencing with siRNA1 reduced cell viability, about 93% 
and 80% in Nthy-ory-3.1 and BCPAP, respectively, and 
increased the percentage of apoptotic cells compared 
to negative control (Figure 3, Panel B - D). Hence, 
Figure 1: HuR expression in thyroid tissues. Panel A. Immunohistochemical evaluation of HuR expression in normal thyroid tissues 
(NT), FAs, PTCs, FTCs and ATCs. Two PTC images are shown to highlight variation in HuR cytoplasmic levels. Panel B. Quantification of 
HuR expression in normal and neoplastic thyroid tissues. It was obtained by using the IHC score, calculated as described in Materials and 
Methods section. Results are shown as mean ± SD. * p < 0.05, ** p < 0.01, **** p < 0.0001 by ANOVA test.
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these data indicate that both in tumorigenic and non-
tumorigenic thyroid cells, HuR plays a positive role in 
cell proliferation.
As HuR is engaged in post-transcriptional gene 
regulation, we performed a high-throughput RNA 
sequencing analysis on Nthy-ori-3.1 and BCPAP 
transfected with siRNA1 or the negative control for 72 
hours. To assess the transcription changes induced by HuR 
silencing, we compared siRNA1 to control-transfected 
cells. Data obtained highlighted that Nthy-ori-3.1 and 
Figure 2: HuR expression in thyroid cell lines. Panel A. Western blot analysis of HuR expression in a non-tumorigenic thyroid cell 
lines (Nthy-ori-3.1) and in six tumorigenic ones (SW1736, FTC133, WRO, FRO, BCPAP and TPC1). Panel B. Densitometric analysis 
of HuR protein levels in thyroid cell lines. Panel C. Immunocytochemical staining of Nthy-ori-3.1 and BCPAP cells. The brown signal 
indicates HuR positivity. Results are shown as mean ± SD. * p < 0.05, ** p < 0.01, **** p < 0.0001 by ANOVA test.
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BCPAP showed a quite different response to HuR 
silencing, as represented in the heat map in Figure 4 (Panel 
A). Expression of 14784 and 14800 genes was detected 
in Nthy-ori-3.1 and BCPAP cell lines, respectively. After 
filtering low quantity reads, results showed that 807 genes 
were differentially expressed after HuR silencing in Nthy-
ory-3.1 (Supplementary Table S1), while, in BCPAP, the 
modified genes were 404 (Supplementary Table S2)(in 
Figure 3: HuR silencing effects on cell viability. Panel A. Nthy-ori-3.1 and BCPAP cells were transfected with non-targeting siRNA 
(NC, negative control) or three different siRNA sequence specific to HuR (5 nM) and collected after 72 h treatment. HuR protein levels 
were analyzed by Western Blot analysis, as described in Materials and Methods section. Panel B-C. Nthy-ori-3.1 (B) and BCPAP (C) were 
transfected to either siRNA1 or siRNA2 or negative control for 72 hours and cell death phenomena was analyzed by Annexin V and PI 
staining. Panel D. Histogram relative to Annexin V/PI analysis.
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Figure 4: HuR silencing effects on gene expression. Panel A. Heat maps showing the hierarchical clustering of RNA targets in 
Nthy-ori-3.1 and BCPAP cell lines. Cells were treated either with siRNA1 or negative control for 72 hours. Results are showed as siRNA1 
compared to control transfected cells. Panel B. Venn diagrams represented the comparison of up-regulated, down-regulated and unmodified 
genes between Nthy-ori-3.1 and BCPAP cell lines after RNA-seq data analysis. The overlap of Nthy-ori-3.1 and BCPAP circles in Venn 
diagrams indicated shared modified genes between Nthy-ori-3.1 and BCPAP cell lines.
Oncotarget7www.impactjournals.com/oncotarget
both cell lines at a log2 fold change >2). In particular, 437 
genes were up-regulated and 370 were down-regulated 
in Nthy-ori-3.1, while, in BCPAP, we identified 273 up-
regulated genes and 131 down-regulated ones. As showed 
in the Venn diagrams, among the up-regulated genes, 67 
were modified in both cell lines and, among the down-
regulated genes, 29 were common between the two cell 
lines (Figure 4, Panel B). Target expression modifications 
induced by HuR silencing were assessed by quantitative 
RT-PCR both in sequenced samples and in replicate 
experiments. For this purpose, we chose 12 deregulated 
genes. The selection was based both on fold change 
values and on their biological function. Results are shown 
in Figure 5. For each selected gene, RNA-seq data were 
confirmed also in replicate experiments, indicating the 
high quality of our transcriptome analysis. In Tables 1 and 
2 are listed the top 20 genes whose expression is modified 
by HuR silencing in both cell lines: as we can see, the 
majority of them belongs to the non-coding transcripts 
family, in particular miRNAs.
HuR-bound RNA profiles
To understand whether the different effects observed 
after HuR silencing in Nthy-ori-3.1 and BCPAP cells 
could be related to a differential HuR binding pattern, we 
Figure 5: Validation of HuR silencing effects on gene expression. Relative expression levels of PLAU, ROBO4, SERPINB2, 
ANGPTL4, ARRB2, LMOD1, ITGB4, PPL, IFIT3, KISS1, ADIRIF and FGFBP1 after HuR silencing. RNA extraction and real time PCR 
are described in Materials and Method section. For each cell lines, the results were normalized against β actin and expressed in arbitrary 
unit, calculated as described in Materials and Methods section. Results are shown as mean ± SD of three different experiments. All silenced 
cell data were statistical significant compared to untreated cells.
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performed a HuR-RIP approach allowing the identification 
of HuR-bound RNA profiles in the two cell lines.
By the high-throughput RIP sequencing analysis, 
we identified 846 and 952 transcripts significantly 
bound by HuR in Nthy-ori-3.1 and BCPAP, respectively. 
Among them, we identified several type of RNA: 
mRNA, miRNA and lncRNA. The HuR-bound RNA 
profiles identified by RIP-seq turned out to be quite 
different between non-tumorigenic and cancer cells. 
Comparing them, we identified 572 transcripts bound 
in both cell lines (Supplementary Table S3), while 
274 RNAs were specifically bound only in Nthy-
ori-3.1 cells (Supplementary Table S4) and 380 RNAs 
in BCPAP cells (Supplementary Table S5). In Figure 
6 (Panel A), we provide a broad overview of RIP-
seq results in terms of number of genes identified as 
significantly bound by HuR.
In order to find RNAs bound by HuR in a larger 
set of tumorigenic cells, we extended the RIP-seq analysis 
to other two PTC cell lines: K1 and TPC1. As shown in 
Figure 6 (Panel B), comparing the results obtained in the 
three tumorigenic cell lines, we identified 442 RNAs that 
were commonly bound by HuR in all of them. Comparing 
these 442 RNAs to those bound by HuR in Nthy-ori-3.1, 
we observed that 114 RNAs were specifically bound by 
HuR only in tumorigenic cell lines (Figure 6, Panel C)
(Supplementary Table S6). Among these tumor cells 
specific HuR targets, we identified 13 genes that are 
already described as involved in tumorigenic processes 
(Table 3) and that may be related to the HuR tumor-
promoting ability in thyroid cancer cells.
In order to support the good outcome of our RIP 
approach, we matched our results with the BioGRID 
public database (http://thebiogrid.org/, accessed 
07/13/2015), in which published genetic and protein 
interaction data are archived. Comparing our RIP-seq 
results with BioGRID records, we observed a matching of 
51%, 46%, 42% and 45% of HuR targets in Nthy-ori-3.1, 
BCPAP, K1 and TPC1 respectively, with the database 
(data not shown). Among interesting HuR targets, already 
Table 1: Top 20 down-regulated and up-regulated genes by HuR silencing in Nthy-ori-3.1
TOP 20 Nthy-ori-3.1 down-regulated genes TOP 20 Nthy-ori-3.1 up-regulated genes
Gene Control FPKM siRNA FPKM Gene Control FPKM siRNA FPKM
MIR103A2 26.53 0 OR5H14 0 0.70
MIR103B2 205.72 0 ACKR1 0 1.19
MIR1227 8.63 0 MIR5193 0 1.35
MIR1231 10.49 0 PTGIR 0 1.39
MIR1260B 12.48 0 BAALCOS 0 1.48
MIR1279 314.85 0 CASC8 0 1.48
MIR1304 11.15 0 CTSE 0 1.79
MIR1324 8.08 0 FDCSP 0 2.03
MIR15A 47.29 0 MIR5572 0 2.08
MIR181B2 12.28 0 MIR548I2 0 2.75
MIR191 13.06 0 CCL4 0 4.53
MIR192 5.77 0 MIR1178 0 4.86
MIR194-1 16.51 0 SNORA16B 0 5.04
MIR2278 14.21 0 MIR1224 0 5.21
MIR27B 10.30 0 MIR492 0 5.58
MIR302C 25.72 0 MIR221 0 5.72
MIR3176 43.99 0 SNORA79 0 6.68
MIR3190 22.54 0 MIR577 0 7.14
MIR3192 17.62 0 MIR1207 0 7.28
MIR320B2 2.41 0 SNORA70B 0 7.43
FPKM= Fragments Per Kilobase Of Exon Per Million Fragments Mapped
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known in other tissues, our data include i.e. HuR, eIF4E, 
BCL2, TP53, XIAP, MDM2, VHL, MYC.
A large amount of data indicates that HuR often 
interacts with its cognate RNAs at 3’UTR level [5, 9, 15]. 
To evaluate if this behavior occurs also in Nthy-ori-3.1, 
BCPAP, K1 and TPC1 cell lines, we analyzed the count 
distribution across different genomic regions, setting a 
minimum coverage per feature of 500 reads, and then 
normalizing count distribution for the number of each 
region present. In this way, we observed that, also in 
our thyroid cells, the 3’UTRs were the regions with the 
highest coverage (Figure 7).
DISCUSSION
HuR is a RNA-binding protein that plays a major 
role in regulation of gene expression [10] and that can 
contribute to tumorigenesis [7]. The HuR function 
is controlled at multiple levels. For example, HuR 
transcription, is positively regulated by the nuclear 
factor (NF)-κB and by Smad, while the abundance of 
HuR mRNA and protein are conditioned upon multiple 
regulatory mechanisms [10]. HuR is able to positively 
regulate its own mRNA modulating cytoplasmic export, 
stabilization, and translation. Furthermore, HuR protein 
is subjected to several post-translational modification, i.e. 
phosphorylation, methylation and ubiquitination, which 
affects HuR cytoplasmic levels, stability and interactions 
with, its targets [8, 10].
Several data indicate that HuR expression and 
localization are modified in cancer cells. In particular, 
a very frequent observation is the increase of HuR 
cytoplasmic localization [4, 16]. The relevance of HuR 
in tumorigenesis is highlighted by the evidence that this 
protein is currently explored as a target for anticancer 
treatment [17, 18]. Nothing is known, so far, about 
HuR expression and function in thyroid follicular cells. 
Therefore, investigation on this protein could provide 
innovative information on molecular mechanisms 
contributing to thyroid cancer. Coherently with data 
Table 2: Top 20 down-regulated and up-regulated genes by HuR silencing in BCPAP
TOP 20 BCPAP down-regulated genes TOP 20 BCPAP up-regulated genes
Gene Control FPKM siRNA FPKM Gene Control FPKM siRNA FPKM
SNORD98 32.08 0 SNORA56 0 0.69
RIIAD1 0.52 0 MIR922 0 54.83
MT1JP 0.53 0 HIST1H4G 0 0.53
CLDN3 0.56 0 DDX26B 0 0.60
PPP1R14A 0.61 0 ZP4 0 0.61
FAM25A 1.13 0 KISS1 0 0.72
MIR5572 1.78 0 GNG8 0 1.24
SNORA70 2.46 0 IFNL2 0 1.24
MIR98 3.20 0 IFNB1 0 1.61
MIR941-2 5.45 0 MIR3689B 0 1.68
MIR765 6.58 0 IFNL1 0 2.12
MIR7110 7.27 0 SCARNA11 0 2.17
MIR569 7.29 0 MIR6129 0 3.32
MIR135A2 7.66 0 MIR5191 0 3.47
MIR10A 7.72 0 MIR5193 0 3.68
MIR567 7.80 0 MIR5189 0 3.71
MIR4441 7.85 0 P2RX6P 0 3.72
MIR6785 7.87 0 MIR454 0 4.07
SNORD23 8.07 0 MIR182 0 4.47
MIR345 8.48 0 MIR3940 0 4.58
FPKM= Fragments Per Kilobase Of Exon Per Million Fragments Mapped.
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Figure 6: HuR-bound RNAs in thyroid cell lines. Panel A. Venn diagrams representing the comparison of HuR RNA target 
identified in Nthy-ori-3.1 and BCPAP cells by RIP-seq analysis. Panel B. Venn diagrams representing the comparison of HuR RNA target 
identified in three PTC cell lines: BPCAP, K1 and TPC1 by RIP-seq analysis. Panel C. Venn diagrams representing the comparison of HuR 
RNA target identified in tumorigenic and non-tumorigenic cell lines.
Oncotarget11www.impactjournals.com/oncotarget
obtained in different neoplasia [19-22], we show that HuR 
is over-expressed in thyroid cancer. Moreover, the amount 
of cytoplasmic HuR appears to be significantly higher 
in thyroid malignancies (PTC, FTC and ATC) compared 
to NT or FA (Figure 1). When thyroid cancer cell lines 
were investigated, HuR over-expression was confirmed 
(Figure 2). Consistently with data obtained in tissues, both 
in Nthy-ori-3.1 and BCPAP cells, HuR localization was 
mostly nuclear, with a major expression in BCPAP. Nthy-
ori-3.1 are non-tumorigenic cells, derived from normal 
thyroid follicular cells immortalized by the SV40 large T 
antigen [23], while BCPAP cells are derived from PTC 
bearing the BRAF V600E and TP53 D259Y mutations 
[24]. Although only BCPAP cells present features of 
invasiveness (i.e. growth in soft agar assay), Nthy-ori-3.1 
and BCPAP grow in vitro with a similar high rate (Figure 
8); therefore, both cell lines must be considered a model 
of thyroid hyper-proliferating cells. In this light, it is 
not surprising that HuR silencing reduced cell growth 
parameters in both cell lines. These results are coherent 
with available data on other cellular models; in fact, HuR 
silencing reduces cell growth of a wide range of cultured 
cells [25-28].
Considering HuR overexpression in thyroid cancer 
tissues as well as the results obtained by HuR silencing, 
indicating a HuR-dependent mechanism of thyroid cancer 
cell survival, this RBP might be consider an innovative 
therapeutic target for thyroid cancer.
How HuR silencing induces similar biological effects 
in Nthy-ori-3.1 and BCPAP cells, though the majority of 
molecular modifications are specific for the single cell 
line? Two, not mutually exclusive, possibilities can be 
put forward. The first is that effects of HuR silencing are 
due to genes modified in both cell lines. Indeed, BIRC3 
is up-regulated in both Nthy-ori-3.1 and BCPAP cells and 
is known to be involved in signaling of cell proliferation 
[29]. The second possibility is that HuR silencing-derived 
biological effects are due to expression modification of 
Table 3: Tumor specific HuR bound RNAs involved in tumorigenic processes
Gene Function Reference number
TM4SF1 Member of the transmembrane 4 superfamily, which mediate signal 
transduction events. This protein is highly expressed in different carcinomas.
[51]
ZKSCAN3 Transcription activator and promoter of cancer cell progression and/or 
migration in various tumors and myelomas.
[52]
EREG Ligand of the EGF receptor/EGFR and ERBB4. Stimulates cell proliferation. [53]
MAP3K1 Component of a protein kinase signal transduction cascade involved in 
tumorigenesis.
[54]
PKN2 PKC-related serine/threonine-protein kinase and Rho/Rac effector protein that 
participates in cell migration, cell adhesion and tumor cell invasion.
[55]
AXL It transduces signals from the extracellular matrix into the cytoplasm. It is 
involved in proliferation, migration, resistance to apoptosis and survival.
[56]
FGF5 The protein encoded by this gene is a member of the fibroblast growth 
factor (FGF) family. This gene was identified as an oncogene, which confers 
transforming potential to mammalian cells.
[57]
THBS1 This protein is an adhesive glycoprotein that mediates cell-to-cell and cell-to-
matrix interactions; it plays roles in platelet aggregation, angiogenesis, and 
tumorigenesis.
[58]
EZR This protein plays a key role in cell surface structure adhesion, migration and 
organization, and it has been implicated in various human cancers.
[59]
CPEB4 CPEB4 regulates a range of biological processes involved in tumor and 
progression,. Moreover, CPEB4 is overexpressed in some human tumor types,
[60]
ITGB1 ITGB1 has been identified as a potential prognosis biomarker in triple negative 
breast cancer.
[61]
SUPV3L1 Major helicase player in mitochondrial RNA metabolism. May protect cells 
from apoptosis.
[62]
RYK Co-receptor of Wnt proteins. RYK is essential for Wnt-5a-dependent 
invasiveness in human glioma.
[63]
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distinct genes between the two cell lines. For example, 
in BCPAP HuR silencing up-regulates IFIT3, which is an 
inhibitor of cell proliferation [30]. Conversely, in Nthy-
ori-3.1, HuR silencing induces overexpression of FOSL1, 
which is involved in control of cell proliferation [31].
A major conclusion of our research is that in two 
cell lines originating from the same cell type (thyroid 
follicular cells) and both having a high proliferation 
rate, HuR shows significantly different spectra of both 
functional and interaction targets. Here, functional 
targets are defined as those whose expression is modified 
by HuR silencing, while interaction targets are those 
delineated by the RIP-seq assay. Our experiments 
indicate that among functional targets, only 96 out 
of 1115 are shared by Nthy-ori-3.1 and BCPAP cells, 
while among interaction targets 572 out of 1226 are 
commonly bound in the two cell lines. The notion that 
HuR is able to recognize distinct RNA spectra, by using 
RIP-chip experiments, has been described also during T 
cells activation. It has been shown, in fact, that, when 
Jurkat cells are stimulated by the phorbol ester PMA, 
only 405 among 1219 probes remain constant after 
4 and 12 hours treatment [32]. Altogether, it could be 
envisaged that variation of HuR bound RNA species 
among cells with distinct biological properties is a 
common phenomenon. Our data represent a proof of 
concept that this variation exists between cells of the 
same origin but with different tumorigenic potential. 
Indeed, by comparison of RIP-seq data obtained in all 
cell lines, we observed a set of 114 HuR-bound RNAs 
common for tumorigenic cell lines and not for non-
tumorigenic cells. An open question is to understand 
which phenotypic characteristics are responsible for 
this HuR behavior in non-tumorigenic and tumorigenic 
cells. Our immunohistochemical data indicate that the 
differences observed between the two cell lines are not 
due to a different protein localization (Figure 2, Panel 
C). Thus, a possible explanation of HuR plasticity, in 
terms of both functional and interaction targets, could be 
related to a difference its post-translational modifications 
in the two cell lines. HuR, indeed, is subjected to several 
post-translational modifications that influence its 
functions and its subcellular localization. For example, 
HuR phosphorylation by Chk2, Cdk1 or p38 and HuR 
methylation by CARM1 regulate both its cytoplasmic 
levels as well as the protein-mRNA interactions [9].
Figure 7: Localization of HuR-RNAs interaction region. Graphical representation of Nthy-ori-3.1, BCPAP, K1 and TPC1 RIP-seq 
count distribution across different genomic features (UTR3, intronic, exonic, UTR5, intergenic and downstream). The count distribution 
was normalized for the number of each region present.
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Another possible event that could influence HuR-
mRNA binding is the presence of different RNA post-
transcriptional modifications on its targets. Nowadays 
more than 100 kinds of RNA modifications have been 
identified and this discovery highlights the hypotesis 
that RNA modifications may act as epigenetic markers 
[33]. The most abundant mRNA modification is N6-
methyl-adenosine (m6A). This RNA modification is 
present in more than three sites per mRNA molecule 
on average and is enriched at the 3’ UTR [34]. Wang 
and colleagues have demonstrated that HuR regulates 
the stability of many mRNAs in embryonic stem cells 
Figure 8: Nthy-ori-3.1 and BCPAP cell lines growth in vitro. Panel A. Colony formation assay of Nthy-ori-3.1, BCPAP and K1. 
Panel B. Histogram representing the number of colonies per cell line. Results are shown as mean ± SD of three different experiments. *** 
p < 0.0001 by Student t test. Panel C. Cell viability of Nthy-ori-3.1, BCPAP and FRO cells was determined by MTT assay after 0, 24, 48 
and 72 h and expressed as fold change respect t0. All samples were run in quadruplicate.
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in a m6A-dependent manner, proving in particular, 
that the m6A methylation loss enhances HuR mRNA 
binding [35].
Our data indicate that in both cell lines, only a 
small fraction of functional targets is also interaction 
targets. In fact, in Nthy-ori-3.1 only 16 functional 
targets are bounded by HuR, while in BCPAP cells 
only 5 RNAs modified by HuR silencing are interaction 
targets (Figure 9). The notion of a minimal overlap 
between HuR functional and interaction targets has 
been also recently observed using a HuR conditional 
knockout model in CD4+ T cell activation [36]. In that 
study, in fact, 2068 “functional” and 271 “interaction” 
HuR targets have been identified, but only 30 were 
shared by the two groups. Even if only few data 
are today available, the minimal overlap between 
“functional” and “interaction” targets seems to be a 
common phenomenon of RBPs. In fact, for the yeast 
Figure 9: Functional and interaction HuR target. Venn diagrams representing the comparison between RNA-Seq (Functional) and 
RIP-Seq (Interaction) HuR-target genes identified in Nthy-ori-3.1 and BCPAP cells. In the circle overlapping area genes that were both 
Functional and Interaction HuR targets.
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Puf3p protein, it has been shown that the expression 
of only 82 out of 1132 interaction targets was modified 
when transcriptomics of parental and Puf3p-deleted 
strains were compared [37]. We have to consider that 
these technological approaches are still new and major 
comprehension of their potential could improve the 
interpretation of data obtained so far. However, the 
accuracy of our RNA-seq analysis is demonstrated by 
the consistency for all tested genes, whose expression 
has been evaluated by qPCR. Moreover, the RIP-
seq analysis quality is proved by its overlap with the 
BIOGRID database: in fact, 51%, 46%, 42% and 45% 
of RNAs found as HuR targets in Nthy-ori-3.1, BCPAP, 
K1 and TPC1, respectively, are also listed in this 
database. Furthermore, the HuR RNA targets identified 
by RIP-seq and also listed in the BIOGRID database 
include several known HuR targets, i.e. HuR, eIF4E, 
BCL2, TP53, XIAP, MDM2, VHL, MYC.
In order to explain the slight overlap between 
functional and interaction HuR targets, the relevance of 
miRNAs as HuR co-actors and/or antagonists must be 
considered [38]. In fact, our RNA-seq analysis showed 
that miRNAs are the most misregulated transcripts after 
HuR silencing. Therefore, we could hypothesize that 
HuR knockdown caused a switch to an alternative gene 
expression program, in order to overcome the RBP 
absence. This may occur by increasing the expression 
of miRNAs operating as HuR co-actors, and by down-
regulating HuR antagonist miRNAs. Such a possibility 
is positively supported by our transcriptomic data. In 
fact, expression of the LET-7, a HuR miRNA co-actor 
[39, 40], was up-regulated in both cell lines upon HuR 
silencing and the opposite phenomenon occurs for miR34a 
expression, a HuR antagonist [39, 41]. miRNAs whose 
expression is modified by HuR silencing might play a 
role in thyroid tumorigenesis. For example, miR181b is 
downregulated upon HuR silencing and it is known that 
its downregulation is associated to promote apoptosis in 
PTCs [42]. Thus, further investigations on the relationship 
between HuR and noncoding RNAs (both lnRNAs and 
miRNAs) could reveal important aspects of thyroid 
tumorigenesis.
In conclusion, our findings indicate that RBP targets 
may be different between cells with the same origin but 
with different aggressiveness. Therefore, investigation 
on this phenomenon could provide relevant information 
to understand the molecular derangements occurring in 
cancer cells.
MATERIALS AND METHODS
Human tissues and cell lines
A series of 12 normal thyroid glands (NTs), 
25 follicular adenomas (FAs), 23 follicular thyroid 
carcinomas (FTCs), 36 papillary thyroid carcinomas 
(PTCs) and 8 anaplastic thyroid carcinomas (ATCs) were 
selected from the files of the Institution of Anatomic 
Pathology of the University of Udine and the most 
representative blocks of each lesion were retrieved from 
the archive. All samples were diagnosed by referral 
pathologists of institutions and then reviewed by a single 
experienced pathologist, thus including only patients 
with a confirmed diagnosis. The study has been approved 
by the “Sapienza” University Ethical Committee.
In this study, we used 8 different thyroid cell lines: 
Nthy-ori-3.1, derived from normal thyroid follicular 
epithelial cells and immortalized by the SV40 large T 
gene; BCPAP, K1 and TPC1, derived from papillary 
thyroid carcinoma; FTC133 and WRO, from follicular 
thyroid carcinoma; FRO and SW1736, from anaplastic 
thyroid cancer. All cell lines have been validated by short 
tandem repeat and tested for being mycoplasma-free.
FRO, TPC1 and FTC133 cells were grown in 
DMEM medium (EuroClone, Milan, Italy) while the 
others were grown in RPMI 1640 medium (EuroClone). 
Both media were supplemented with 10% fetal bovine 
serum (Gibco Invitrogen, Milan, Italy), 2 mM L-glutamine 
(EuroClone) and 50 mg/ml gentamicin (Gibco Invitrogen). 
Cells were grown in a humidified incubator (5% CO2 in air 
at 37°C) (Eppendorf AG, Hamburg, Germany).
Immunohistochemistry
A tissue microarray was created with representative 
tumor-bearing areas of the selected thyroid tissues. Briefly, 
5 μM formalin-fixed paraffin tissue sections mounted on 
SuperFrost Plus slides (Menzel-Gläser, Braunschweig, 
Germany) were placed in the PT Link pre-treatment 
module (DAKO A/S, Glostrup, Denmark), which performs 
automatically the entire pre-treatment process of de-
paraffinization, rehydration, and epitope retrieval using the 
Low pH Target Retrieval Solution (0.001 M citrate buffer 
pH 6.0) at 98 °C for 40 min from DAKO. Endogenous 
peroxidase activity was blocked by incubation in the 
Peroxidase Block solution (DAKO) for 5 minutes.
As for cell cultures, Nthy-ori-3.1 and BCPAP cells 
were fixed with 5% glacial acetic acid in ethanol for 
10 min at 4°C, and rinsed with 0.1% saponin (Sigma 
Chemical Co, St Louis, Missouri, USA) in phosphate-
buffered saline (PBS). This PBS–saponin solution was 
used for all subsequent washing steps.
The tissue microarray and the cell cultures slides 
were incubated with primary rabbit polyclonal antiserum 
to HuR (Millipore) diluted 1:50 for 60 minutes at room 
temperature. After washing, slides were incubated with 
the DAKO EnVision FLEX System (DAKO) according 
to manufacturer’s guidelines. For reaction visualization, 
3-3 diaminobenzidine tetrahydrochloride was used as 
chromogen. The sections were counterstained with Mayer’s 
hematoxylin. Using light microscopy, the entire section was 
scanned at high-power magnification (400x) and nuclear 
immunostaining was evaluated by using the H-score 
method. The H-score is a well-established semi-quantitative 
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evaluation of immunohistochemical data [43]. It is calculated 
by multiplying the percentage of immunoreactive cells and 
the intensity of the staining, which is graded as low (score 
1), moderate (score 2) or strong (score 3). Thus, the range 
of possible scores was from 0 to 300. Each cellular location 
(cytoplasm and nucleus) was separately scored. H-score was 
determined by two experienced pathologists: for each sample 
the final H-score corresponds to the mean value of these two 
independent evaluations.
Protein extraction and western blot
Total protein extraction was performed as previously 
described [44]. Briefly, Nthy-ori-3.1, SW1736, FRO, 
WRO, FTC133, TPC1 and BCPAP cells were harvested 
by scraping and lysed with total lysis buffer (Tris HCl 50 
mM pH8, NaCl 120 mM, EDTA 5 mM, Triton 1%, NP40 
1%, protease inhibitors).
For nuclear and cytoplasmic protein extraction, 
Nthy-ori-3.1 and BCPAP cells were lysed by using two 
buffer with different ionic force: B1 (HEPES pH 7.9 10 
mM, KCl 10 mM, MgCl2 0.1 mM, EDTA pH 8 0.1 mM) 
for cytoplasmic proteins extraction and B2 (HEPES pH 
7.9 20 mM, NaCl 420 mM, MgCl2 1.5 mM, EDTA pH 
8 0.1 mM, glicerolo 5%) for nuclear proteins extraction.
For Western Blot analysis, proteins were 
electrophoresed on 12% SDS-PAGE and then transferred 
to nitrocellulose membranes (GE Healthcare, Little 
Chalfont, UK), saturated with 5% non-fat dry milk in 
PBS/0.1% Tween 20. The membranes were then incubated 
overnight with rabbit polyclonal anti-HuR antibody 
1:500 (Millipore) or rabbit anti-β-actin antibody 1:1000 
(Abcam, Cambridge, UK). The day after, membranes 
were incubated for 2 h with anti-rabbit immunoglobulin 
coupled to peroxidase 1:4000 (Sigma-Aldrich). Blots were 
developed using UVITEC Alliance LD (UVITec Limited, 
Cambridge, UK) with the SuperSignal Technology 
(Thermo Scientific Inc).
HuR silencing
For transient silencing of endogenous HuR, 
TriFECTa RNAi Kit (Integrated DNA Technologies Inc, 
Coralville, IA, USA) was used following manufacturer’s 
instructions and a previously published procedure [45]. 
Briefly, a ‘universal’ negative control duplex, that targets 
a site absent in human genome, was used. Three different 
siRNA oligonucleotides (siRNA1, siRNA2 and siRNA3) 
were transfected at a concentration of 5 nM using 
DharmaFECT 1 Transfection reagent (Thermo Scientific 
Inc, Waltham, MA, USA), according to manufacturer’s 
instructions. The concentration of 5 nM was set 
performing dose-response studies (data not shown). The 
day before transfection, cells were plated in antibiotics-
free medium. Cells were harvested 72 h after transfection 
and gene-silencing efficiency was evaluated by protein 
levels analysis.
Annexin V assay
Nthy-ori-3.1 and BCPAP cells, transfected with 
siRNA oligonucleotides or control, were washed with 
cold PBS, transferred to a polystyrene round-bottomed 
flow tube (Falcon, Becton Dickinson, Franklin Lakes, 
NY) and resuspended in 195 µL of 1x binding buffer (BB 
10 mM; HEPES/NaOH, pH 7.4, 140 mM NaCl, and 2.5 
mM CaCl2). 5 µL of Fluorescein-conjugated Annexin V 
(Annexin V-FITC; Bender Med Systems, Vienna, Austria) 
was added and samples were incubated for 10 minutes at 
room temperature. After washing, cells were resuspended 
in 190 µL of BB in which 10 µL of propidium iodide 
stock solution (final concentration 1 µg/mL) was added. 
Flow cytometry analysis was performed on CyAN, Dako 
Cytomation using the Summit software (Flow cytometer, 
Beckman Coulter). Forward scatter (FSC) and side 
scatter (SSC) were acquired in linear mode. FITC and 
PI fluorescent signals derived from 488 nm excitation 
were detected in logarithmic mode at FL1/PMT3 and 
FL2/PMT4, with FITC 530/30 nm filters, and PI 585/42 
nm filters, respectively, and a FL1/2 560 nm short pass 
dichroic filter. Signals for forward and side scatter and 
fluorescence were collected for 104 cells using the forward 
light scatter parameter as the master signal. Data are 
expressed as mean fluorescence intensity (FI) values.
Library preparation and sequencing
Total RNA from Nthy-ori-3.1 and BCPAP cell 
lines was extracted with RNeasy mini kit according to 
manufacturer’s instructions (Qiagen, Hilden, Germany). 
TruSeq Stranded Total RNA with Ribo-Zero Human/
Mouse/Rat kit (Illumina, San Diego, CA) has been used 
for library preparation following the manufacturer’s 
instructions, starting with 200 ng of good quality RNA 
(R.I.N. >7) as input. Both RNA samples and final libraries 
were quantified by using the Qubit 2.0 Fluorometer 
(Invitrogen, Carlsbad, CA) and quality tested by Agilent 
2100 Bioanalyzer RNA Nano assay (Agilent technologies, 
Santa Clara, CA). Libraries were then processed with 
Illumina cBot for cluster generation on the flowcell, 
following the manufacturer’s instructions and sequenced 
on 50 bp single-end mode at the on HiSeq2500 (Illumina, 
San Diego, CA). The CASAVA 1.8.2 version of the 
Illumina pipeline was used to processed raw data for both 
format conversion and de-multiplexing.
RNA-Seq bioinformatics analysis
Raw sequence files were subjected to quality control 
analysis using FastQC (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/). In order to avoid low 
quality data, adapters were removed by Cutadapt [46] 
and lower quality bases were trimmed by ERNE [47]. For 
the analysis of differentially expressed genes, the quality-
checked reads were processed using the TopHat version 
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2.0.0 package (Bowtie 2 version 2.2.0) as FASTQ files 
[48-50]. The reads were mapped to the human reference 
genome GRCh37/hg19. Reads abundance was evaluated 
and normalized by using Cufflinks [49] for each gene and 
FPKM (Fragments Per Kilobase Of Exon Per Million 
Fragments Mapped) values were obtained.
Cuffdiff from the Cufflinks 2.2.0 package was 
used to calculate the differential expression levels and to 
evaluate the statistical significance of detected alterations 
between control and silenced samples, in both cell lines. 
For further analysis, we selected effective data using three 
criteria: a) FPKM values > 0.5; b) log2 fold-change >2 
and c) q-value (false discovery rate (FDR)) <0.005.
Gene expression assays
150 ng of total RNA of Nthy-ori-3.1 and BCPAP cells, 
transfected with siRNA1 or control, were reverse transcribed 
to cDNA using random exaprimers and SuperScript III 
reverse transcriptase (Life Technologies, Carlsbad, CA, 
USA). Real-time PCR was performed using Platinum 
Sybr Green QPCR supermix (Life Technologies) with the 
ABI Prism 7300 Sequence Detection Systems (Applied 
Biosystems). The ΔΔCT method, by means of the SDS 
software (Applied Biosystems), was used to calculate mRNA 
levels. Oligonucleotide primers were purchased from Sigma-
Aldrich and their sequences are available upon request.
RNA-binding protein immunoprecipitation
The RNA-binding protein immunoprecipitation 
(RIP) was performed using EZ-Magna RIP kit (Millipore) 
according to manufacturer’s instructions.
In order to perform RIP assay, Nthy-ory-3.1, 
BCPAP, K1 and TPC1 cells were scraped in PBS 
containing protease inhibitors and then resuspended in RIP 
lysis buffer (Millipore) containing protease and RNase 
inhibitors.
Magnetic Beads Protein A/G were incubated 
overnight with 5 μg of rabbit polyclonal anti-HuR RIPAb+ 
antibody (Millipore) or normal Rabbit IgG (Millipore) as 
negative control. The day after, samples were added to 
antibody-bead complexes and incubated overnight. 10% 
of samples was stored as total input.
After washings, immune-complexes and input were 
eluted and treated with proteinase K and heated at 55°C 
for 30 minutes to digest the protein. RNA was purified 
with phenol/chloroform extraction followed by ethanol 
precipitation. RNA obtained from RIP was sequenced and 
analyzed as described above.
Cell viability
Methylthiazolyldiphenyl-tetrazolium bromide (MTT) 
was applied to test cell viability. Nthy-ori-3.1, BCPAP and 
FRO cells (3000 cells/well) were plated onto 96-well plates 
in 200 μl medium/well and were allowed to attach to the 
plate for 24 h (t0). Plates were then incubated for 24, 48 and 
72 h. The cell medium was then replaced with 200 μl fresh 
medium/well containing 0.5 mg/ml MTT (Sigma-Aldrich) 
and cultivated for another 4 h darkened in the cells incubator. 
The supernatant was removed, 100 μl/well of DMSO (Sigma-
Aldrich) were added and the absorbance at 570 nm was 
measured. All experiments were run in quadruplicate and cell 
viability was expressed as a fold change respect t0.
Soft agar assay
Nthy-ori-3.1 and BCPAP cell lines clonogenic 
activity was evaluated by soft agar assay. Briefly, 10000 
cells per plate were suspended in 4 ml of complete 
medium containing 0.25% agarose and then seeded to 
the top of a 1% agarose complete medium layer in 6 
cm plates. The colonies were counted by the inverted 
microscope Leica DMI-600B (Leica Microsystems Ltd., 
Heerbrugg, Switzerland). Data are representative of three 
independent experiments.
Statistical analysis
mRNA and protein levels, cell viability and 
apoptosis levels were expressed as means ± SD, and 
significances were analyzed with either the Student’s t-test 
or one-way ANOVA, both performed with GraphPAD 
Software for Science (San Diego, CA, USA).
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